PRNewswire (Tue, 8-Sep 8:00 AM ET)
Globe Newswire (Tue, 11-Aug 11:00 AM ET)
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Tue, 11-Aug 7:31 AM ET)
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
PRNewswire (Tue, 4-Aug 8:00 AM ET)
PRNewswire (Wed, 15-Jul 7:45 AM ET)
Market Chameleon (Thu, 14-May 7:14 AM ET)
Market Chameleon (Thu, 12-Mar 4:14 AM ET)
Market Chameleon (Thu, 30-Oct 5:52 AM ET)
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Therapeutics trades on the NASDAQ stock market under the symbol INTS.
As of October 8, 2026, INTS stock price declined to $3.68 with 19,072 million shares trading.
INTS has a beta of 0.96, meaning it tends to be less sensitive to market movements. INTS has a correlation of 0.01 to the broad based SPY ETF.
INTS has a market cap of $12.01 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INTS traded as high as $286.00 and as low as $3.21.
The top ETF exchange traded funds that INTS belongs to (by Net Assets): VXF.
INTS has underperformed the market in the last year with a price return of -47.8% while the SPY ETF gained +16.8%. INTS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.0% and -10.2%, respectively, while the SPY returned +3.8% and +0.8%, respectively.
INTS support price is $3.57 and resistance is $4.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INTS shares will trade within this expected range on the day.